NLRP3 Inflammasome Activation Hinges on a Novel Phase Separation Mechanism
Researchers discover NLRP3 undergoes liquid-liquid phase separation to ignite inflammation, explaining how diverse stressors trigger the same pathway.
Summary
A 2025 Cell Research study reveals that NLRP3 inflammasome activation begins with signal-induced phase separation — a biophysical condensation process — rather than a single molecular trigger. The palmitoyltransferase ZDHHC7 continuously palmitoylates NLRP3 in resting cells, lowering the threshold for phase separation. An intrinsically disordered region (IDR) in NLRP3's FISNA domain, containing three conserved hydrophobic residues, drives multivalent weak interactions enabling condensate formation. Diverse stimuli including potassium efflux, imiquimod, palmitate, and cardiolipin all induce NLRP3 conformational changes that trigger phase separation. Surprisingly, amphiphilic molecules — including common di-alcohols and chemotherapy drugs doxorubicin and paclitaxel — directly reduce NLRP3 solubility to activate it independently of ZDHHC7, revealing an unexpected inflammatory side effect of cancer treatments.
Detailed Summary
Why this matters: NLRP3 inflammasome dysregulation underlies a wide spectrum of inflammatory, metabolic, and neurodegenerative diseases, yet the fundamental question of how structurally unrelated stimuli all converge to activate the same protein has remained unanswered for decades. This study provides a unifying biophysical answer with direct therapeutic implications.
What was studied: Researchers at Peking University used genome-wide CRISPR-Cas9 screening in a gain-of-function NLRP3 THP-1 cell line (R262W), followed by cell biology, biochemical, and in vitro reconstitution experiments to dissect the molecular basis of NLRP3 activation. They focused on the role of the palmitoyltransferase ZDHHC7 and an intrinsically disordered region (IDR) in the NLRP3 FISNA domain.
Key results: ZDHHC7 continuously palmitoylates NLRP3 at Cys130 and Cys261 (human) or Cys126 (mouse) in unstimulated cells, reducing NLRP3 solubility without triggering activation. This tonic lipid modification acts as a molecular primer, lowering the energetic threshold for phase separation. Upon encountering activating stimuli — K⁺ efflux, imiquimod, palmitate, or the mitochondrial lipid cardiolipin — NLRP3 undergoes conformational changes that drive it into liquid-like condensates with properties consistent with phase separation (fluorescence recovery after photobleaching, sensitivity to 1,6-hexanediol). Three conserved hydrophobic residues in the FISNA IDR were shown to be essential for multivalent weak interactions mediating condensation. Strikingly, amphiphilic molecules including 1,6-hexanediol (a classic phase separation disruptor), doxorubicin, and paclitaxel activated NLRP3 by directly reducing its solubility and inducing phase separation, entirely bypassing the need for ZDHHC7 palmitoylation.
Implications: The study proposes three mechanistic modes of NLRP3 activation all converging on phase separation: (1) intracellular ion changes inducing conformational change and condensation; (2) direct NLRP3-interacting molecules inducing conformational change and condensation; and (3) amphiphilic solubility-reducing molecules directly triggering condensation. This framework elegantly explains the longstanding puzzle of how chemically diverse stimuli activate a single sensor. It also raises concern that widely used chemotherapy drugs may inadvertently promote inflammasome-driven inflammation in patients.
Caveats: The full-text excerpt is truncated and some downstream mechanistic detail and in vivo validation data may not have been fully captured. Most experiments were conducted in cell lines (THP-1, HeLa, HEK293T, iBMDM) and in vitro systems; the clinical translatability of phase separation-targeted interventions requires further investigation in primary human cells and animal disease models.
Key Findings
- ZDHHC7 tonically palmitoylates NLRP3 at Cys130/Cys261 in resting cells, priming it for activation without triggering it.
- An IDR in the NLRP3 FISNA domain with three conserved hydrophobic residues drives phase separation via multivalent weak interactions.
- All tested NLRP3 stimuli (K⁺ efflux, imiquimod, palmitate, cardiolipin) induce NLRP3 conformational change and phase separation.
- Chemotherapy drugs doxorubicin and paclitaxel directly activate NLRP3 via phase separation, independent of ZDHHC7 palmitoylation.
- ABHD13 acts as a counterbalancing depalmitoylase that negatively regulates NLRP3 activation.
Methodology
Genome-wide CRISPR-Cas9 screening in a gain-of-function NLRP3 THP-1 cell line identified ZDHHC7 and ABHD13. Palmitoylation was confirmed via acyl-biotin exchange (ABE), acyl-PEG exchange (APE), and click chemistry assays. Phase separation was characterized by fluorescence microscopy, FRAP, and sensitivity to amphiphilic disrupting agents in both cellular and in vitro reconstitution systems.
Study Limitations
Most experiments were performed in transformed cell lines or overexpression systems rather than primary human immune cells, limiting direct clinical extrapolation. The full mechanistic detail of how conformational changes couple to phase separation initiation remains to be structurally resolved. In vivo validation in disease-relevant animal models was not captured in the available text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.